Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicroDep low-dose psilocybin for moderate major depressive disorder
ACTRN12623001064695Phase 2Recruiting
- Sponsor
- Macquarie University
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in major depressive disorder (MDD) (2 arms), sponsored by Macquarie University. Primary endpoint: Primary: change in GRID-Hamilton Depression Rating Scale from baseline to week 6. Started Feb 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623001064695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001064695.